New Insights on the Role of Janus Kinase (JAK) Inhibition in Rheumatoid Arthritis and
“Do You Know JAK?”
Release Date: August 25, 2017
Last Reviewed: August 17, 2017
Expiration Date: August 25, 2018
Time to Complete Activity:  1.0 hour
*This activity expired for credit on August 25, 2018 and is no longer available for credit
Roy Fleischmann, MD, MACR
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Co-Medical Director
Metroplex Clinical Research Center
Dallas, TX
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, NY
Joseph Markenson, MD, MACR, FACP
Professor of Clinical Medicine
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, NY
This activity is provided by Paradigm Medical Communications, LLC.                        
Target Audience
This activity has been designed to address the educational needs of physicians specializing in rheumatology. It may also benefit nurses, nurse practitioners, PAs, and other members of the multidisciplinary team who care for patients with rheumatoid arthritis (RA).
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Describe the role of Janus kinase (JAK) in the chronic cycle of inflammation associated with RA.
  • Identify the intracellular immune and anti-inflammatory effects of JAK inhibition on RA.
  • Select appropriate candidates for treatment of RA with JAK inhibitors
Physician Accreditation Statement
Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 Category 1 credits for completing this activity.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Commercial Support
This activity is supported by an educational grant from Pfizer Inc.
Instructions for Participation
To receive a CME certificate of participation, participants must:
  • Follow instructions to register or log in with your professional information and complete the pretest.
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest.
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 audio and video.
Supported Browsers:
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Technical Support: If you have any technical problems or playback issues, please email us at

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Roy Fleischmann, MD, MACR
Advisory Boards:  AbbVie Inc., Eli Lilly and Company, Pfizer Inc
Speaker Bureau:  Pfizer Inc
Clinical Trials: AbbVie Inc., Eli Lilly and Company, Pfizer Inc
Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Consulting Fees: AbbVie Inc., Eli Lilly and Company, Merck & Co., Inc, Pfizer Inc
Speaker Bureau: AbbVie Inc., Celgene Corporation, Horizon Pharma plc, Novartis Pharmaceuticals Corporation, Pfizer Inc
Stockholder: AbbVie Inc., Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Pfizer Inc, Regeneron Pharmaceuticals, Inc (Self and Spouse)
Joseph Markenson, MD, MACR, FACP
Consulting Fees:  Celgene Corporation Eli Lilly and Company, Merck & Co., Inc
Fees for non-CME Services: Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck & Co., Inc, Pfizer Inc
Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC, has implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm. Paradigm accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC, is committed to protecting the privacy of those who participate in the activities (herein referred to as "website") located at The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm to continuously improve the learning experience.
Paradigm Medical Communications, LLC, does not transfer, sell, or share personal information with outside parties. Paradigm will not otherwise disclose personal information unless required to in a legal process. Paradigm staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at
© 2017 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.